A few months after I graduated from Stanford’s business school in 2013, Theranos was generating buzz on campus—and not all of it was good.
One evening, I found myself in a dinner party conversation with a group of some of the university’s brightest scientific minds. When talk landed on the still mostly-unknown medical technology startup that had raised nearly $100 millio…
Read more